Shahswar, Rabia Ganser, Arnold
Published in
Expert review of hematology
The combined use of the BCL-2 inhibitor venetoclax with azacitidine now is the standard of care for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy with outcomes exceeding those achieved with hypomethylating agents alone. Venetoclax in combination with intensive chemotherapy is also increasingly used both as frontline as...
Wang, Xiaoning Guo, Jiashuo Liu, Yan Zheng, Na Xu, Shaohan Wu, Lianhui Yuan, Ruirui Xue, Liying Li, Jie
Published in
Frontiers in Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of
Elsabah, Hesham Ghasoub, Rola El Omri, Halima Benkhadra, Maria Cherif, Honar Taha, Ruba Y.
Published in
Frontiers in Oncology
Introduction Venetoclax is a BCL-2 inhibitor with proven efficacy in patients with multiple myeloma (MM) and translocation t(11;14). However, its role in plasma cell leukemia (PCL) remains unclear. Herein, we aimed to report a case of relapsed MM with secondary PCL and t(11;14) achieving complete (CR) and durable remission with venetoclax therapy. ...
Corradi, Giulia Forte, Dorian Cristiano, Gianluca Polimeno, Andrea Ciciarello, Marilena Salvestrini, Valentina Bandini, Lorenza Robustelli, Valentina Ottaviani, Emanuela Cavo, Michele
...
Published in
Frontiers in Immunology
Acute myeloid leukemia (AML) is an aggressive heterogeneous disease characterized by several alterations of the immune system prompting disease progression and treatment response. The therapies available for AML can affect lymphocyte function, limiting the efficacy of immunotherapy while hindering leukemia-specific immune reactions. Recently, the t...
Zhang, Ludan Ge, Rui Pan, Deng Yue, Pengjie Zhang, Jingwen Bian, Renjie Yan, Xiaojing
Published in
Frontiers in Pharmacology
Introduction: Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Thus, this study aimed to examine the effectiveness and safety of VEN-HMA therapy in patients with MDS and C...
Fatima, Narjis Shen, Yandong Crassini, Kyle Burling, Olivia Thurgood, Lauren Iwanowicz, Edwin J Lang, Henk Karanewsky, Donald S Christopherson, Richard I Mulligan, Stephen P
...
Published in
Leukemia & lymphoma
Despite advances in treatment, a significant proportion of patients with chronic lymphocytic leukemia (CLL) will relapse with drug-resistant disease. The imipridones, ONC-201 and ONC-212, are effective against a range of different cancers, including acute myeloid leukemia (AML) and tumors of the brain, breast, and prostate. These drugs induce cell ...
Wang, Lida Song, Jiwu Xiao, Xiangming Li, Dianfang Liu, Tianmeng He, Xiaopo
Published in
Journal of chemotherapy (Florence, Italy)
Because of lacking of head-to-head comparison between venetoclax and IDH1/IDH2 inhibitors (ivosidenib/enasidenib) for newly diagnosed unfit patients with acute myeloid leukemia (AML), the optimal option for these patients still remains undefined. We searched relevant published reports. Three RCTs with 180 IDH1 mutant and 165 IDH2 mutant patients we...
MAQUET, Claire DE PRIJCK, Bernard JASPERS, Aurélie Tassin, Françoise Keutgens, Aurore Beguin, Yves De Voeght, Adrien
peer reviewed / Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive haematological disease with a grim prognosis. The majority of patients at diagnosis are elderly (typical age range: 60 to 70 years) and seldom fit enough to receive intensive induction therapy. We report here the case of a 76-year-old patient with signi ficant...
Angotzi, Francesco Lessi, Federica Leoncin, Matteo Filì, Carla Endri, Mauro Lico, Albana Visentin, Andrea Pravato, Stefano Candoni, Anna Trentin, Livio
...
Published in
Frontiers in Oncology
Venetoclax (VEN) has been shown to play a synergistic effect in combination with hypomethylating agents (HMAs) in the frontline treatment of acute myeloid leukemia (AML). However, the potential role of this therapy in the relapsed/refractory (R/R) AML setting, still needs to be further unveiled. The aim of the current study was to retrospectively o...
Xu, Jing Li, He Wang, Zhongwang Wang, Mengyao Li, Qian Hang, Xiaohang Xu, Juan Ji, Jie Chen, Chong Liu, Yu
...
Published in
Molecular carcinogenesis
Acute promyelocytic leukemia (APL) is generally driven by PML::RARA, but approximately 2% of variant APL patients do not contain this fusion gene and pose challenges in diagnosis and treatment. Here, we reported an aggressive APL patient with variant TNRC18::RARA fusion gene, who was resistant to standard differentiation induction therapy consistin...
